Takeda (TAK) Q1 2026 Earnings Call Transcript
Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.
How this was made
The 30-second read
Why it matters
Key decision-relevant items include FY2026 revenue and core operating profit guidance, adjusted free cash flow range, capex outlook, and specific regulatory and launch timing for Orzeyful and rusfertide, alongside clinical efficacy updates for zasocitinib and TAK-928.
Market read
This is a company-specific earnings/guidance and catalyst update that can drive repricing around launch execution, cash flow trajectory, and pipeline probability-weighting.
What to watch
The transcript emphasizes working-capital and a one-time $200M payment tied to Protagonist opt-out; traders may discount these as non-recurring and focus on whether transformation savings truly offset higher operating expenses into FY2026.
Background
The piece summarizes Takeda’s Q1 2026 earnings call, including financial performance, pipeline/clinical readouts, and FY2026 guidance.
Ticker impact
Takeda reported Q1 2026 revenue of JPY 1.22T, core operating profit down 0.5% at constant FX, and reiterated FY2026 guidance including FCF and capex ranges.
Moderate two-sided reaction risk: upside from clearer launch timelines and pipeline progress, offset by weaker adjusted free cash flow and generic Vyvanse erosion.
The article contains multiple quantified datapoints (revenue, core profit, AFCF decline, net debt/EBITDA, FY2026 revenue and FCF guidance, capex outlook) plus specific regulatory and clinical timing, which can reprice the stock, but it is a transcript-style summary rather than a fresh filing.
Market effects
Biopharma investors may re-focus on launch execution and cash conversion as Takeda highlights working-capital impacts and transformation savings.
China and Japan regulatory timing for Orzeyful can influence regional managed-care and hospital formularies expectations.
US FDA PDUFA timing for rusfertide (Aug 2026) is a cross-market catalyst that can affect sentiment toward hepcidin-mimetic competitors and payer discussions.
Counterpoint
The headline growth narrative may be overstated because constant-FX revenue is slightly down and adjusted free cash flow fell nearly 64% YoY, suggesting cash earnings quality is deteriorating.
Key entities
- companyTakeda Pharmaceutical Company Limited
US-listed issuer (TAK) reporting Q1 2026 results and FY2026 guidance, with multiple pipeline and launch timing updates.
- companyProtagonist Therapeutics
Counterparty in a rusfertide co-promotion opt-out, with Takeda paying $200M and taking sole commercialization responsibility.
- regulatorFDA
US regulatory body with an August 2026 PDUFA timeline referenced for rusfertide.
